CIC Dumps With Exact Questions and Answers

The correct answer is A, "Observe all steps for reprocessing," as this is the most important process for the infection preventionist (IP) to review when evaluating a third-party reprocessor for single-use devices. According to the Certification Board of Infection Control and Epidemiology (CBIC) guidelines, the reprocessing of single-use devices (SUDs) by third-party entities must adhere to stringent infection control standards to ensure they are safe for reuse and do not contribute to healthcare-associated infections (HAIs). Observing all steps—such as cleaning, disinfection, sterilization, packaging, and quality control—allows the IP to directly assess compliance with manufacturer instructions, regulatory requirements (e.g., FDA guidelines), and best practices (e.g., AAMI ST91) (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.3 - Ensure safe reprocessing of medical equipment). This hands-on evaluation is critical because any deviation in the reprocessing chain can compromise device sterility and patient safety.

Option B (review the facility's blueprints and policies) provides context about the physical layout and procedural framework, but it is a preliminary step that does not directly verify the reprocessing process’s effectiveness. Option C (ensure air and water cultures are performed regularly) is important for monitoring environmental contamination risks, particularly in sterile processing areas, but it is a supportive measure rather than the primary focus of evaluating the reprocessor’s core activities. Option D (obtain feedback from other IPs who use the reprocessor) offers valuable peer insights, but it is subjective and secondary to direct observation, which provides firsthand evidence of compliance and performance.

The priority on observing reprocessing steps aligns with CBIC’s emphasis on ensuring the safety and efficacy of reprocessed medical devices, a key responsibility for IPs when outsourcing to third-party reprocessors (CBIC Practice Analysis, 2022, Domain III: Infection Prevention and Control, Competency 3.5 - Evaluate the environment for infection risks). This process enables the IP to identify specific weaknesses, validate adherence to standards, and make informed decisions about the reprocessor’s suitability.

The CBIC Certified Infection Control Exam Study Guide (6th edition) emphasizes that when evaluating new medical or surgical equipment, the first priority for the infection preventionist is reviewing the manufacturer’s instructions for use (IFU). The IFU provides critical information regarding cleaning, disinfection, sterilization, handling, storage, and maintenance requirements, all of which directly impact infection prevention and patient safety.

Robotic surgical equipment often includes complex components, lumens, joints, and reusable instruments that may require specialized reprocessing methods. The IP must ensure that the facility has the infrastructure, staffing, competency, and resources to meet the IFU requirements before purchase. Failure to comply with manufacturer instructions places the organization at risk for ineffective reprocessing, device contamination, healthcare-associated infections, and regulatory noncompliance.

The other options are secondary considerations. Cost (Option A) and operative time impact efficiency and budgeting but do not address infection risk. Storage between cases (Option C) is important but cannot be properly evaluated without first understanding IFU requirements. Length of surgery (Option B) may influence infection risk but is not within the primary evaluative scope of infection prevention during equipment selection.

For the CIC® exam, it is essential to recognize that IFU review is the foundational step in product evaluation. Infection preventionists must confirm that equipment can be safely and consistently reprocessed according to manufacturer specifications before any operational or financial considerations are addressed.

==========

The Certification Study Guide (6th edition) explains that interpretation of hepatitis B serologic markers is a fundamental competency for infection preventionists, particularly in occupational health and exposure management. In this scenario, the patient is HBsAg negative, indicating no current hepatitis B infection; anti-HBs positive, indicating immunity; and anti-HBc negative, meaning there has been no prior natural infection with hepatitis B virus.

This specific serologic pattern is diagnostic of immunity due to vaccination. The hepatitis B vaccine contains only purified hepatitis B surface antigen, not core antigen. As a result, vaccinated individuals develop antibodies to the surface antigen (anti-HBs) but do not develop antibodies to the core antigen (anti-HBc). The study guide emphasizes this distinction as the key factor in differentiating vaccine-induced immunity from immunity due to past infection.

The incorrect options reflect different serologic patterns. Previous hepatitis B infection would produce a positive anti-HBc result. A recent blood transfusion does not confer long-term immunity or this marker pattern. Low-level infectivity would require detectable surface antigen or core antibody.

This question reflects a classic CIC exam topic: recognizing the serologic profile of vaccine-induced immunity. Correct interpretation supports appropriate employee health decisions, post-exposure management, and immunization program evaluation.